Expression of myeloid Src-family kinases is associated with poor prognosis in AML and influences Flt3-ITD kinase inhibitor acquired resistance
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Expression of myeloid Src-family kinases is associated with poor prognosis in AML and influences Flt3-ITD kinase inhibitor acquired resistance
Authors
Keywords
-
Journal
PLoS One
Volume 14, Issue 12, Pages e0225887
Publisher
Public Library of Science (PLoS)
Online
2019-12-03
DOI
10.1371/journal.pone.0225887
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Identification of Pyrrolo[2,3-d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia
- (2019) Xue Yuan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia
- (2019) Taylor M. Weis et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Selective Inhibition of the Myeloid Src-Family Kinase Fgr Potently Suppresses AML Cell Growth in Vitro and in Vivo
- (2018) Mark C. Weir et al. ACS Chemical Biology
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Functional genomic landscape of acute myeloid leukaemia
- (2018) Jeffrey W. Tyner et al. NATURE
- The Src family kinase Fgr is a transforming oncoprotein that functions independently of SH3-SH2 domain regulation
- (2018) Kexin Shen et al. Science Signaling
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth
- (2017) Mark C. Weir et al. PLoS One
- Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397
- (2015) C. C. Smith et al. Cancer Discovery
- Trimmomatic: a flexible trimmer for Illumina sequence data
- (2014) Anthony M. Bolger et al. BIOINFORMATICS
- SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia
- (2014) Alexandre Puissant et al. CANCER CELL
- Activating FLT3 Mutants Show Distinct Gain-of-Function Phenotypes In Vitro and a Characteristic Signaling Pathway Profile Associated with Prognosis in Acute Myeloid Leukemia
- (2014) Hanna Janke et al. PLoS One
- FLT3 Inhibitors in AML: Are We There Yet?
- (2014) Akshay Sudhindra et al. Current Hematologic Malignancy Reports
- Kinase crystal identification and ATP-competitive inhibitor screening using the fluorescent ligand SKF86002
- (2014) Lorien J. Parker et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents
- (2013) C. Dos Santos et al. BLOOD
- A Pyrrolo-Pyrimidine Derivative Targets Human Primary AML Stem Cells in Vivo
- (2013) Y. Saito et al. Science Translational Medicine
- A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3
- (2012) Marshall A. Lichtman BLOOD CELLS MOLECULES AND DISEASES
- Small-Molecule Inhibitors of the c-Fes Protein-Tyrosine Kinase
- (2012) Sabine Hellwig et al. CHEMISTRY & BIOLOGY
- A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff
- (2012) Pablo Cingolani et al. FLY
- Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
- (2012) Catherine C. Smith et al. NATURE
- CHASM and SNVBox: toolkit for detecting biologically important single nucleotide mutations in cancer
- (2011) Wing Chung Wong et al. BIOINFORMATICS
- The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
- (2010) A. McKenna et al. GENOME RESEARCH
- Identification of Therapeutic Targets for Quiescent, Chemotherapy-Resistant Human Leukemia Stem Cells
- (2010) Y. Saito et al. Science Translational Medicine
- AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
- (2009) P. P. Zarrinkar et al. BLOOD
- FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro
- (2009) N. von Bubnoff et al. CANCER RESEARCH
- A quantitative analysis of kinase inhibitor selectivity
- (2008) Mazen W Karaman et al. NATURE BIOTECHNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now